Myelofibrosis is a chronic and life-threatening blood disease. There is a need for accurate risk stratification approaches to guide personalized medicine decisions for these patients. To address this need, we developed a non-invasive blood-based test that is cost-effective, scalable and accurate. Through the Lab2Market program we will explore the market and develop the business case […]
Read More